TScan Therapeutics (TCRX) Cash from Investing Activities (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Cash from Investing Activities of -$70000.0 for Q1 2026, down 100.52% year-over-year from $13.5 million in Q1 2025, and down 100.47% quarter-over-quarter from $14.8 million in Q4 2025.
TScan Therapeutics (TCRX) Cash from Investing Activities (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Cash from Investing Activities for 7 consecutive years, with -$70000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 100.52% year-over-year to -$70000.0; the TTM figure through Mar 2026 stood at $95.8 million (up 227.28% YoY), while the FY2025 annual figure was $109.4 million, up 307.88% from the prior year.
- Cash from Investing Activities retreated to -$70000.0 in Q1 2026 per TCRX's latest filing, from $14.8 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $48.4 million in Q2 2025 and bottomed at -$82.4 million in Q3 2024.
- Historically, Cash from Investing Activities has averaged -$487941.2 across 5 years, with a median of -$420000.0 in 2023.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities slumped 14384.43% — and 2024, when it soared 4415.39%.
- TScan Therapeutics' Cash from Investing Activities stood at -$1.4 million in 2022, then jumped by 238.93% to $1.9 million in 2023, then surged by 1326.71% to $27.3 million in 2024, then sank by 45.67% to $14.8 million in 2025, then slumped by 100.47% to -$70000.0 in 2026.
- Business Quant data shows TCRX's Cash from Investing Activities at -$70000.0 in Q1 2026, $14.8 million in Q4 2025, and $32.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | -465,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -465,000.00 |
| Jun 30, 2026 | -465,000.00 |
| Mar 31, 2026 | -70,000.00 |
| Mar 31, 2026 | -70,000.00 |
| Dec 31, 2025 | 14.83 Mn |
| Dec 31, 2025 | 14.83 Mn |
| Sep 30, 2025 | 32.58 Mn |
| Sep 30, 2025 | 32.58 Mn |
| Jun 30, 2025 | 48.44 Mn |
| Jun 30, 2025 | 48.44 Mn |
| Mar 31, 2025 | 13.53 Mn |
| Mar 31, 2025 | 13.53 Mn |
| Dec 31, 2024 | 27.29 Mn |
| Dec 31, 2024 | 27.29 Mn |
| Sep 30, 2024 | -82.35 Mn |
| Sep 30, 2024 | -82.35 Mn |
| Jun 30, 2024 | -33.72 Mn |
| Jun 30, 2024 | -33.72 Mn |
| Mar 31, 2024 | 36.16 Mn |
| Mar 31, 2024 | 36.16 Mn |